PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31422497-1 2019 INTRODUCTION: Ki-67 labeling index assessed by immunohistochemical assays has been shown useful in assessing the risk of recurrence for estrogen receptor (ER)-positive HER2-negative breast cancers (BC) and distinguishing Luminal A-like from Luminal B-like tumors. Phenobarbital 221-228 estrogen receptor 1 Homo sapiens 155-157 33000282-3 2020 In the present study, it was revealed that E2F5 gene silencing caused a significant reduction in the proliferation rate of breast cancer MCF7 (ER-positive luminal-type) and MDA-MB-231 (TNBC-type) cells. Phenobarbital 155-162 estrogen receptor 1 Homo sapiens 143-145 33123289-1 2020 Breast cancer is one of the most common malignancies worldwide, while the luminal types (ERalpha positive) accounts for two third of all breast cancer cases. Phenobarbital 74-81 estrogen receptor 1 Homo sapiens 89-96 32531861-4 2020 ESR1 is involved in the reabsorption of luminal fluid during the transit of spermatozoa from the testis to the head of the epididymis which is important for their survival and maturation during epididymal storage. Phenobarbital 40-47 estrogen receptor 1 Homo sapiens 0-4 32771039-3 2020 Previously, we reported a recurrent ESR1 fusion called ESR1-CCDC170 in 6-8% of the luminal B breast cancers that has a worse clinical outcome after endocrine therapy. Phenobarbital 83-90 estrogen receptor 1 Homo sapiens 36-40 32771039-3 2020 Previously, we reported a recurrent ESR1 fusion called ESR1-CCDC170 in 6-8% of the luminal B breast cancers that has a worse clinical outcome after endocrine therapy. Phenobarbital 83-90 estrogen receptor 1 Homo sapiens 55-59 32548262-9 2020 We propose RING1B as a key regulator of the dynamic, liganded-ERalpha transcriptional regulatory circuit in luminal BC. Phenobarbital 108-115 estrogen receptor 1 Homo sapiens 62-69 31610144-5 2020 In response to hormonal signaling, Areg emanating from estrogen receptor (ER)-positive luminal cells, induce the expression of Rspo1 in ER-negative luminal cells. Phenobarbital 87-94 estrogen receptor 1 Homo sapiens 55-72 31610144-5 2020 In response to hormonal signaling, Areg emanating from estrogen receptor (ER)-positive luminal cells, induce the expression of Rspo1 in ER-negative luminal cells. Phenobarbital 87-94 estrogen receptor 1 Homo sapiens 74-76 31610144-5 2020 In response to hormonal signaling, Areg emanating from estrogen receptor (ER)-positive luminal cells, induce the expression of Rspo1 in ER-negative luminal cells. Phenobarbital 87-94 estrogen receptor 1 Homo sapiens 136-138 31610144-5 2020 In response to hormonal signaling, Areg emanating from estrogen receptor (ER)-positive luminal cells, induce the expression of Rspo1 in ER-negative luminal cells. Phenobarbital 148-155 estrogen receptor 1 Homo sapiens 55-72 31610144-5 2020 In response to hormonal signaling, Areg emanating from estrogen receptor (ER)-positive luminal cells, induce the expression of Rspo1 in ER-negative luminal cells. Phenobarbital 148-155 estrogen receptor 1 Homo sapiens 74-76 31610144-5 2020 In response to hormonal signaling, Areg emanating from estrogen receptor (ER)-positive luminal cells, induce the expression of Rspo1 in ER-negative luminal cells. Phenobarbital 148-155 estrogen receptor 1 Homo sapiens 136-138 31932695-0 2020 ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Phenobarbital 18-25 estrogen receptor 1 Homo sapiens 63-80 30315845-0 2019 Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3Kalpha inhibition through the transcriptional regulation of ERalpha. Phenobarbital 30-37 estrogen receptor 1 Homo sapiens 124-131 29301444-4 2018 Another chemically diverse group of xenobiotics including phenobarbital, DDT, can activate the nuclear receptor CAR and in some cases estrogen receptors ESR1 and ESR2. Phenobarbital 58-71 estrogen receptor 1 Homo sapiens 153-157 34845001-3 2022 In contrast, luminal A tumors express ERalpha and can undergo endocrine therapy for treatment. Phenobarbital 13-20 estrogen receptor 1 Homo sapiens 38-45 34911733-7 2022 Finally, biochemical experiments indicate that luminal-like DTPs survive via estrogen receptor-dependent induction of SGK3, leading to rewiring of the PI3K/AKT/mTORC1 pathway to enable AKT-independent mTORC1 activation. Phenobarbital 47-54 estrogen receptor 1 Homo sapiens 77-94 34517157-12 2021 Combined expression of ESR1, FOXA1 and GATA3 represents a molecular signature of luminal subtypes. Phenobarbital 81-88 estrogen receptor 1 Homo sapiens 23-27 34944881-8 2021 CONCLUSION: Our data supports the role of apoERalpha in maintaining the luminal phenotype of BC cells by extensively regulating gene expression at the alternative splicing level. Phenobarbital 72-79 estrogen receptor 1 Homo sapiens 42-52 34707101-6 2021 NRIP1 is not only upregulated in luminal A patients and cell lines but also regulates breast cancer-related genes, including PR, ESR1 and CCND1. Phenobarbital 33-40 estrogen receptor 1 Homo sapiens 129-133 34845227-3 2021 A major barrier to the understanding of the ERalpha-pathway biology and therapeutic discoveries is the restricted repertoire of luminal ERalpha + breast cancer models. Phenobarbital 128-135 estrogen receptor 1 Homo sapiens 44-51 34845227-3 2021 A major barrier to the understanding of the ERalpha-pathway biology and therapeutic discoveries is the restricted repertoire of luminal ERalpha + breast cancer models. Phenobarbital 128-135 estrogen receptor 1 Homo sapiens 136-143 34725332-5 2021 Furthermore, we found a set of hormone-responsive lineage-specific transcription factors, FOXA1, GATA3, ERalpha, directly drove high expression of ARSD through chromatin looping in luminal subtype BC cells. Phenobarbital 181-188 estrogen receptor 1 Homo sapiens 104-111 34831189-3 2021 ERalpha is expressed in a subset of luminal cells corresponding to less than 10% of normal mammary epithelial cells and in over 70% of breast tumors (ER+ tumors), but the basis for its selective expression in normal or cancer tissues remains incompletely understood. Phenobarbital 36-43 estrogen receptor 1 Homo sapiens 0-7 34831189-7 2021 In particular, we discuss the impact of genetic alterations, chromatin modifications, and enhanced expression of other luminal transcription regulators on ESR1 expression in tumor cells. Phenobarbital 119-126 estrogen receptor 1 Homo sapiens 155-159 34073233-9 2021 Tumours with an elevated expression of markers associated with luminal differentiation (KRT20, ERBB2, ESR1) were associated with a higher chance of pCR (55% vs. 15.8%, p = 0.009). Phenobarbital 63-70 estrogen receptor 1 Homo sapiens 102-106 35563193-3 2022 In the hormone-receptor-positive Luminal A and Luminal B molecular subtypes of clinical breast cancer, conventional endocrine therapy predominantly targets estrogen receptor function and estrogen biosynthesis and/or growth factor receptors. Phenobarbital 33-40 estrogen receptor 1 Homo sapiens 156-173 34609431-6 2021 According to chi-squared analysis of molecular cancer subtypes correlation to receptors and Ki67 index, we found significant associations between both luminal A and luminal B HER2-negative subtypes and hormone receptors (ER, PR). Phenobarbital 151-158 estrogen receptor 1 Homo sapiens 221-223 34609431-6 2021 According to chi-squared analysis of molecular cancer subtypes correlation to receptors and Ki67 index, we found significant associations between both luminal A and luminal B HER2-negative subtypes and hormone receptors (ER, PR). Phenobarbital 165-172 estrogen receptor 1 Homo sapiens 221-223 35418303-8 2022 Accordingly, CHK1 and ERalpha activations are correlated in ERalpha-positive BC cell lines, and the ATR:CHK1 pathway controls ERalpha stability and cell proliferation in luminal A BC cells. Phenobarbital 170-177 estrogen receptor 1 Homo sapiens 126-133 33412751-3 2020 Luminal breast cancer is characterized by a relatively high expression of estrogen receptor (ER) and progesterone receptor (PR) genes, which are expressed in breast luminal cells. Phenobarbital 165-172 estrogen receptor 1 Homo sapiens 74-91 35195972-2 2022 For example, estrogen receptor (ER) positive breast cancer is composed of two different subtypes (luminal A and luminal B) with different biologic processes and distinct prognosis. Phenobarbital 98-105 estrogen receptor 1 Homo sapiens 13-30 35195972-2 2022 For example, estrogen receptor (ER) positive breast cancer is composed of two different subtypes (luminal A and luminal B) with different biologic processes and distinct prognosis. Phenobarbital 98-105 estrogen receptor 1 Homo sapiens 32-34 35195972-2 2022 For example, estrogen receptor (ER) positive breast cancer is composed of two different subtypes (luminal A and luminal B) with different biologic processes and distinct prognosis. Phenobarbital 112-119 estrogen receptor 1 Homo sapiens 13-30 35195972-2 2022 For example, estrogen receptor (ER) positive breast cancer is composed of two different subtypes (luminal A and luminal B) with different biologic processes and distinct prognosis. Phenobarbital 112-119 estrogen receptor 1 Homo sapiens 32-34 33894309-2 2021 We have previously shown that activation and nuclear accumulation of MRTFA mediate endocrine resistance of estrogen receptor alpha (ERalpha) positive breast cancers by initiating a partial transition from luminal to basal-like phenotype and impairing ERalpha cistrome and transcriptome. Phenobarbital 205-212 estrogen receptor 1 Homo sapiens 107-130 33894309-2 2021 We have previously shown that activation and nuclear accumulation of MRTFA mediate endocrine resistance of estrogen receptor alpha (ERalpha) positive breast cancers by initiating a partial transition from luminal to basal-like phenotype and impairing ERalpha cistrome and transcriptome. Phenobarbital 205-212 estrogen receptor 1 Homo sapiens 132-139 33011748-5 2021 Moreover, high mRNA level of TRPS1 was found in all four subtypes of breast carcinoma including ER/PR-positive luminal A and B types, HER2-positive type, and basal-type/TNBC. Phenobarbital 111-118 estrogen receptor 1 Homo sapiens 96-98 33511077-15 2020 Conclusion: A heterogeneous distribution of ER within the tumor in IHC appeared as an EFS-8y prognosticator in luminal non-metastatic breast cancers. Phenobarbital 111-118 estrogen receptor 1 Homo sapiens 44-46 33412751-3 2020 Luminal breast cancer is characterized by a relatively high expression of estrogen receptor (ER) and progesterone receptor (PR) genes, which are expressed in breast luminal cells. Phenobarbital 165-172 estrogen receptor 1 Homo sapiens 93-95